- Home
- APLT vs ATOS Comparison
APLT vs ATOS Comparison
Compare APLT & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- ATOS
- Stock Information
- Founded
- APLT 2016
- ATOS 2009
- Country
- APLT United States
- ATOS United States
- Employees
- APLT N/A
- ATOS N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- ATOS Health Care
- Exchange
- APLT Nasdaq
- ATOS Nasdaq
- Market Cap
- APLT 128.0M
- ATOS 113.7M
- IPO Year
- APLT 2019
- ATOS 2012
- Fundamental
- Price
- APLT $0.65
- ATOS $0.83
- Analyst Decision
- APLT Buy
- ATOS Strong Buy
- Analyst Count
- APLT 7
- ATOS 3
- Target Price
- APLT $6.10
- ATOS $7.00
- AVG Volume (30 Days)
- APLT 7.5M
- ATOS 886.8K
- Earning Date
- APLT 03-05-2025
- ATOS 11-12-2024
- Dividend Yield
- APLT N/A
- ATOS N/A
- EPS Growth
- APLT N/A
- ATOS N/A
- EPS
- APLT N/A
- ATOS N/A
- Revenue
- APLT N/A
- ATOS N/A
- Revenue This Year
- APLT N/A
- ATOS N/A
- Revenue Next Year
- APLT $2,622.90
- ATOS N/A
- P/E Ratio
- APLT N/A
- ATOS N/A
- Revenue Growth
- APLT N/A
- ATOS N/A
- 52 Week Low
- APLT $0.60
- ATOS $0.77
- 52 Week High
- APLT $10.62
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- APLT 20.60
- ATOS 27.85
- Support Level
- APLT $0.60
- ATOS $0.91
- Resistance Level
- APLT $0.74
- ATOS $0.94
- Average True Range (ATR)
- APLT 0.09
- ATOS 0.06
- MACD
- APLT 0.21
- ATOS -0.00
- Stochastic Oscillator
- APLT 13.53
- ATOS 1.62
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.